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Abbreviations
ACE Angiotensin-converting enzyme inhibit-
ors (drugs for high blood pressure and
heart failure)
AGATE Arbeitsgemeinschaft Anaphylaxie – Train-
ing und Edukation (“working group ana-
phylaxis—training and education”)
AIT Allergen immunotherapy
AMWF Association of Scientific Medical Soci-
eties
COVID-19 Coronavirus disease 2019
DAAB German Allergy and Asthma Association
(patient organization)
DGAKI German Society for Allergology and Clin-
ical Immunology
NSAIDs Nonsteroidal anti-inflammatory drugs
The most important aspects in a nutshell
 Anaphylaxis is always an emergency, so quick action
is indicated.
 The medicines for immediate help must always be
carried along.
 Get an anaphylaxis passport/anaphylaxis emer-
gency plan.
 Recognize anaphylaxis: Familiarize yourself with
the onset of symptoms and how anaphylactic re-
actions can manifest themselves (see Anaphylaxis
Passport/Emergency Plan).
 Epinephrine is the emergencymedication of choice:
if in doubt, use the epinephrine auto-injector.
 If the epinephrine auto-injector has been used, al-
ways call 112.
 Practice handling the epinephrine auto-injector
with the training pen.
 Informyour personal and social environment about
anaphylaxis: Close relatives and caregivers should
also be familiar with the use of emergency medica-
tions.
 You do not need to hide your condition: Be open
about your allergy and the risk of anaphylaxis. Ask
about relevant allergens when you visit a restaurant
or go out for dinner.
 You are not alone; there are more and more people
with anaphylaxis.
 Get support and more information through AGATE
anaphylaxis training (www.anaphylaxieschulung.
de) and the German Allergy and Asthma Associa-
tion (www.daab.de).
Development of the guideline
After the German Society of Allergology and Clinical
Immunology (DGAKI) of 2017 had commissioned the
working group “Anaphylaxis” to update the existing
guideline on the acute treatment of anaphylaxis, the
first task was to recruit experts from sibling societies
as well as from neighboring disciplines, but also from
neighboring countries and frompatient organizations.
It was possible to involve not only the subspecialty
of allergology but also the (sub)specialities anesthe-
siology and intensive care medicine, dermatology,
pediatrics, internal medicine, oto-rhino-laryngol-
ogy, emergency medicine, pharmacology, pneumol-
ogy, and theoretical surgery (for the methodology of
guideline development). The allergological societies
from Austria and Switzerland are represented as well
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as the patient organization Deutscher Allergie- und
Asthmabund (DAAB). In continuous e-mail exchange,
but also in almost twice-yearly physical meetings
in the context of conferences at various locations
in Germany, the consensus was reached, which has
been reflected in the now adopted guideline. Finally,
a paragraph on the problem of allergy and COVID-19
was added. In January 2021, the guideline was made
available in German and English to the two journals
Allergo Journal/Allergo Journal International and Al-
lergologie/Allergologie select and submitted to the Ar-
beitsgemeinschaft Wissenschaftlicher Medizinischer
Fachgesellschaften (AWMF).
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Who is the guideline aimed at?
The guideline—as an abridged version of the medical
guideline “Acute Therapy and Management of Ana-
phylaxis—Update 2021”—is primarily aimed at pa-
tients at risk of anaphylaxis as well as their relatives
and persons who care for and look after affected per-
sons at risk of anaphylaxis.
What does “anaphylaxis” mean?
Anaphylaxis is the most severe form of an acute al-
lergic immediate reaction that can be potentially life-
threatening.
It manifests itself in various organ systems, most
commonly the skin, respiratory tract, gastrointestinal
tract and cardiovascular system. The symptoms usu-
ally start acutely and can progress rapidly. An anaphy-
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lactic reaction is classified as an emergency and must
be treated immediately.
Depending on the organs affected and the intensity
of the reaction, the treatment procedure is carried out
by the patient himself, by caregivers or by medical
personnel called in.
How does an anaphylactic reaction manifest
itself? What are the symptoms?
A distinction is made between objective symptoms,
i.e., symptoms that can be seen or measured, such
as hives, vomiting, or a drop in blood pressure, and
subjective symptoms, i.e., symptoms perceived exclu-
sively by the patient, such as itching on the palms of
the hands and soles of the feet or in the genital area,
metallic taste, itching or burning in the mouth area,
or nausea. Often, at the onset of an anaphylactic re-
action, these subjective general symptoms may mani-
fest as milder discomfort and may be accompanied by
feelings of anxiety or disorientation. In children, this
manifests as restlessness, drowsiness, or withdrawal
behavior.
Skin: The skin often shows redness, wheals (hives) or
tissue swelling, especially of the lips or eyes (so-called
“angioedema”), even on skin areas that have not had
direct contact with the trigger (e.g., after insect bite or
consumption of food).
Gastrointestinal tract: Nausea, cramping, abdomi-
nal pain, vomiting or diarrhea may occur here, as well
as an involuntary urge to urinate or defecate.
Respiratory tract: Typical signs in the upper respi-
ratory tract are, in addition to runny nose, swelling of
the uvula and tongue, as well as tingling and burn-
ing in the throat or on the palate, which can some-
times manifest as slurred speech, difficulty swallow-
ing, or wheezing sounds when inhaling. In the lungs,
there may be constriction of the bronchi with cough-
ing, shortness of breath, and with whistling sounds
(called “wheezing”) and even respiratory failure.
Cardiovascular system: Due to a dilation and in-
creased permeability of the vessels, a lot of fluid from
the bloodstream can seep into the tissue within a short
time, which can lead to dizziness, clouding of con-
sciousness, drop in blood pressure, increase in heart
rate (pulse), unconsciousness and even collapse or
shock. Direct symptoms to the heart such as arrhyth-
mias are also possible.
What is the course of anaphylactic reactions?
An anaphylactic reaction can occur within minutes
and symptoms can intensify very quickly. However,
there are also anaphylactic reactions that build up
over the period of an hour and progress slowly. How-
ever, a reaction may also spontaneously stop and re-
cede.
The risk and course of recurrent reactions in the
future cannot be predicted with certainty. Symptoms
may vary in nature, expression, and severity with each
reaction.
The severity of a reaction depends on how much
and via which route the allergen was ingested, but can
also be influenced by nonspecific factors, for exam-
ple, simultaneous physical stress, psychological stress,
acute infections, alcohol or certain medications (so-
called augmentation or summation factors).
In addition, underlying diseases such as severe
cardiovascular disease, existing and poorly treated
asthma, mastocytosis (proliferation of mast cells in
various organs of the body), and advanced age can
be risk factors for severe reactions. Medications
that increase the risk of anaphylaxis include beta-
blockers (often prescribed for high blood pressure
or cardiac arrhythmias), ACE inhibitors (for high
blood pressure), or certain painkillers and rheuma-
tism medications (nonsteroidal anti-inflammatory
drugs, NSAIDs).
What are common triggers of an anaphylactic
reaction?
In adults, the most common triggers of anaphylaxis
are insect venoms (e.g., wasp or bee), drugs (e.g.,
painkillers, antibiotics), and foods (e.g., peanuts,
hazelnuts, wheat, spices, or shrimp); in children,
foods, for example, peanuts, hazelnuts, cashew, cow’s
milk, or egg top the list.
How is anaphylaxis treated?
Treatment is based on whether the reaction is occur-
ring for the first time or the risk of anaphylaxis is
known and an emergency kit is already available.
If an emergency kit is available, the procedure is de-
cided according to the organs affected and the severity
of the reaction. Roughly, we distinguish between an
incipient anaphylaxis (in the passport “yellow”) and
a severe reaction (in the passport “red”).
What medications are available for immediate
relief?
Usually, three or four different medications are pre-
scribed individually for the emergency kit for imme-
diate relief, which should be carried together with the
anaphylaxis passport as an emergency kit (Table 1).
How do I recognize a severe anaphylactic
reaction?
A severe reaction is defined by the fact that the lungs
or cardiovascular system are involved (e.g., in case of
respiratory distress or unconsciousness) or two organ
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Table 1 Medications for the emergency kit for immediate aid
Drug Function Has an effect Dosage form
Adrenaline Stabilizes the circulation, expands the respiratory
tract, relaxes the intestinal muscles
Few minutes Auto injector
Antihistamine Has a decongestant and antipruritic effect. Stabilizes
fluid loss into the skin.
About 30min (depending on prepara-
tion and form of preparation)
Liquid, droplets, (melting-/
lozenges) tablets
Cortisone Has an anti-inflammatory, decongestant effect About 60min Juice, suppositories, tablets
Asthma emergency spray (e.g.,
salbutamol, fenoterol)
Expands the airways (prescribed in case of asthma/
known respiratory symptoms)
5–10min Spray, powder for inhalation
systems are affected (e.g., skin with hives and gas-
trointestinal tract with vomiting). Additional symp-
toms can be found in the Anaphylaxis Passport and
Anaphylaxis Emergency Plan.
What to do in case of severe reaction and
emergency kit available?
1. Adrenaline: In the event of a severe reaction, it
is most important that the adrenaline auto-injec-
tor is used immediately by the affected person
or by bystanders or accompanying persons. The
epinephrine auto-injector automatically adminis-
ters a predosed amount of epinephrine into the
outer thigh via pressure.
2. Positioning: positioning should be performed ac-
cording to symptoms, that is,
a. for circulatory problems: lie down and slightly
raise your legs,
b.in case of unconsciousness: stable lateral posi-
tion,
c. In case of predominant respiratory symptoms:
Upper body upright.
3. Asthma emergency spray (if available): If shortness
of breath occurs, the bronchodilator asthma emer-
gency spray (e.g., salbutamol, fenoterol) should be
given, if available.
4. Emergency call (112): According to this, the emer-
gency number 112 should be called immediately to
get professional help.
If two ormore people are on the scene, the adminis-
tration of emergency medication and the placing of
the emergency call should be done in parallel.
5. Antihistamine and cortisone: After these emergency
measures have been taken, the antihistamine (anti-
allergic) and cortisone should also be administered.
Further care will then be provided by emergencymed-
ical services, with, for example, intravenous access for
volume infusion as well as oxygen supply.
In case of severe reactions, inpatient observation
for 24h is recommended, as sometimes symptoms
may reappear after 6–8h (so-called “biphasic reac-
tion”).
What to do if a mild reaction starts and
emergency kit is available?
If there are “only” allergic reactions on the skin, such
as hives, redness, wheals, or in the gastrointestinal
tract, such as nausea, vomiting, “only” the emergency
call can be made at first and the antihistamine and
cortisone given, especially if it is unclear whether an
allergen ingestion has really occurred. However, if
the symptoms worsen, the epinephrine auto-injector
should be applied immediately and proceed as de-
scribed above (severe reaction).
What to do in case of first anaphylactic reaction
when an emergency kit for immediate help is not
yet available?
If emergency medication is not yet available for self-
help, the emergency call must be made immediately
when an anaphylactic reaction is suspected so that
treatment can be given as quickly as possible by the
medical personnel called in. Patients should be posi-
tioned as described above.
What can be done prophylactically?
After successful treatment of anaphylaxis, it is im-
portant to educate those affected about the clinical
picture and to strive for identification of the trigger
through allergy diagnostics (if possible, referral to an
allergist). In addition, the above-mentioned “emer-
gency kit for immediate relief” should be prescribed;
the use of the individual medications must be ex-
plained in detail and practiced. Recommendations
to prevent recurrence of reactions are also important,
especially in the case of food allergy, an individually
adapted therapeutic elimination diet. Here, advice
should be given by a specialized nutritionist. In in-
sect venom allergy, causal treatment by allergen im-
munotherapy (AIT) should be sought, if possible. In
the case of drug allergy, it is important not only to
avoid the triggering drugs, but also to test alternative
drugs, which is usually done by a provocation test un-
der in-patient conditions.
In addition to the self-help emergency kit, a written
plan “Anaphylaxis Passport/Anaphylaxis Emergency
Plan” is given for the management of possible new re-
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actions. In this, the prescribed medication is entered
by the physician in the weight-adapted dose.
When is a second epinephrine auto-injector
prescribed?
Prescription of a second additional epinephrine auto-
injector is recommended for patients with:
 Particularly severe anaphylaxis in the past
 High body weight (over 100kg)
 Uncontrolled bronchial asthma
 Poor accessibility to the nearest emergency care
provider
 Particularly high risk of severe anaphylaxis (e.g.
mastocytosis) or for
 Organizational reasons, for example, childcare cen-
ter, school or according to the family situation.
Important: the medications for immediate relief
must always be with the patient!
At a minimum, the epinephrine auto-injector should
either be carried by the person at risk for anaphylaxis
or be accessible to a caregiver at all times.
What else should be considered regarding
epinephrine auto-injectors?
The epinephrine auto-injectors currently available in
Germany do not differ in substance (epinephrine), but
do differ in dose, shelf life, needle length and han-
dling. For this reason, preparations that a patient has
been trained to handle should not be interchanged if
possible (e.g., for economic reasons by the pharma-
cist); patients should pay attention to this when the
medication is prescribed and, if necessary, the physi-
cian be reminded that it is essential to tick the “aut
idem” box on the prescription.
For emergency medications, the expiration date
must be observed and replacements must be pro-
vided in good time. Important for the practice: dis-
card expired products only when the new preparation
is available and carried. However, there is a possibility
of weaker effect due to expired products.
Where can I get more information, training,
contacts?
AGATEanaphylaxis training: Standardized and qual-
ity-controlled training programs are offered through
“Arbeitsgemeinschaft Anaphylaxie—Training und Edu-
kation” (AGATE). The training focuses on the practi-
cal aspects of self-treatment, with role-plays including
use of the epinephrine auto-injector, allergen avoid-
ance strategies and coping with fear of re-allergen
contact. Age-appropriate training is given to the
patients themselves, but also to their parents and
caregivers.
German Allergy and Asthma Association (DAAB):
As a patient organization, the DAAB is the contact for
questions about everyday management with anaphy-
laxis (allergen avoidance, daycare, school, travel, etc.)
In addition to the standardized anaphylaxis passport/
emergency plan (see below), other information ma-
terials (brochures, shopping guides, restaurant cards,
certificates for air travel, etc.) and aids (see below)
can be obtained from the DAAB. Online seminars on
everyday and emergency management of anaphylaxis
are offered for patients, parents as well as daycare
centers and schools, and contacts such as allergy-
specialized nutritionists can be found.
Resources
Auto-injector trainer (training pen): This is an
adrenaline auto-injector without medication and
needle, with the help of which the application and
handling can be practiced. They are available from all
manufacturers of epinephrine auto-injectors and can
be obtained free of charge from them as well as from
pharmacies or the DAAB.
Anaphylaxis passport: Document issued by a doc-
tor containing information on the person concerned,
the prescribed medication, and on the recognition of
anaphylactic reactions and the measures to be taken
in an emergency. It is kept together with the medica-
tion and always carried along.
Anaphylaxis emergency plan: Document with the
same information as the anaphylaxis passport in DIN
A4 format to pass on to third parties (e.g., daycare
center, school, employer) or the other environment.
Storage bags: They are available through some
epinephrine auto-injector manufacturers, the DAAB
or via the Internet.
Addendum: a few words about Covid-19
vaccination and allergy
Anaphylactic reactions after vaccination are possible
but very rare, for COVID-19 vaccines at a frequency of
1–10 per 1 million.
In case of known anaphylaxis against vaccines,
drugs—especially injected substances—or if the trig-
ger is unclear, prior allergological clarification is rec-
ommended.
Do not vaccinate individuals with anaphylaxis to
ingredients of the intended vaccine, for example,
polyethylene glycol or tromethamine.
For most allergy sufferers, COVID-19 vaccination is
safe.
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